These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 33385289)

  • 1. Clinical usefulness of the 3-tier classification according to the proportion of morphological patterns for patients with pathological stage I invasive lung adenocarcinoma.
    Osawa J; Shimada Y; Maehara S; Hagiwara M; Kakihana M; Kajiwara N; Ohira T; Matsubayashi J; Ikeda N
    Gen Thorac Cardiovasc Surg; 2021 Jun; 69(6):943-949. PubMed ID: 33385289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positive EGFR mutation status is a risk of recurrence in pN0-1 lung adenocarcinoma when combined with pathological stage and histological subtype: A retrospective multi-center analysis.
    Ito M; Miyata Y; Tsutani Y; Ito H; Nakayama H; Imai K; Ikeda N; Okada M
    Lung Cancer; 2020 Mar; 141():107-113. PubMed ID: 32035371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second predominant subtype predicts outcomes of intermediate-malignant invasive lung adenocarcinoma†.
    Ito M; Miyata Y; Yoshiya T; Tsutani Y; Mimura T; Murakami S; Ito H; Nakayama H; Okada M
    Eur J Cardiothorac Surg; 2017 Feb; 51(2):218-222. PubMed ID: 28186287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of epidermal growth factor receptor mutation and the presence of high-grade patterns is associated with recurrence in resected stage I lung adenocarcinoma.
    Kondo Y; Ichinose J; Ninomiya H; Hashimoto K; Matsuura Y; Nakao M; Ishikawa Y; Okumura S; Satoh Y; Mun M
    Interact Cardiovasc Thorac Surg; 2022 Jul; 35(2):. PubMed ID: 35266536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.
    Kadota K; Sima CS; Arcila ME; Hedvat C; Kris MG; Jones DR; Adusumilli PS; Travis WD
    Am J Surg Pathol; 2016 Dec; 40(12):1579-1590. PubMed ID: 27740967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic impact of lung adenocarcinoma predominance classification relating to pathological factors in lobectomy, the Japanese Joint Committee of Lung Cancer Registry Database in 2010.
    Ito H; Date H; Shintani Y; Miyaoka E; Nakanishi R; Kadokura M; Endo S; Chida M; Yoshino I; Suzuki H;
    BMC Cancer; 2022 Aug; 22(1):875. PubMed ID: 35948946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does the histologic predominance of pathological stage IA lung adenocarcinoma influence the extent of resection?
    Ito H; Nakayama H; Murakami S; Yokose T; Katayama K; Miyata Y; Okada M
    Gen Thorac Cardiovasc Surg; 2017 Sep; 65(9):512-518. PubMed ID: 28593420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of epidermal growth factor receptor gene mutation in resected lung adenocarcinoma.
    Deng C; Zhang Y; Ma Z; Fu F; Deng L; Li Y; Chen H
    J Thorac Cardiovasc Surg; 2021 Sep; 162(3):664-674.e7. PubMed ID: 32747123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of predominant subtype in pathological stage II-III lung adenocarcinoma with epidermal growth factor receptor mutation.
    Kitagawa S; Zenke Y; Taki T; Aokage K; Sakai T; Shibata Y; Izumi H; Nosaki K; Umemura S; Matsumoto S; Yoh K; Sakamoto N; Sakashita S; Kojima M; Tsuboi M; Goto K; Ishii G
    Lung Cancer; 2024 Feb; 188():107453. PubMed ID: 38160515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of the new IASLC/ATS/ERS classification of clinical stage IA lung adenocarcinoma.
    Murakami S; Ito H; Tsubokawa N; Mimae T; Sasada S; Yoshiya T; Miyata Y; Yokose T; Okada M; Nakayama H
    Lung Cancer; 2015 Nov; 90(2):199-204. PubMed ID: 26341957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Correlation between the new lung adenocarcinoma classification and epidermal growth factor receptor mutation].
    Zhang XD; Liu DR
    Beijing Da Xue Xue Bao Yi Xue Ban; 2018 Aug; 50(4):640-644. PubMed ID: 30122764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significant difference in recurrence according to the proportion of high grade patterns in stage IA lung adenocarcinoma.
    Jeon HW; Kim YD; Sim SB; Moon MH
    Thorac Cancer; 2021 Jul; 12(13):1952-1958. PubMed ID: 34037324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive Study of Surgical Treated Lung Adenocarcinoma with Ground Glass Nodule Component.
    Xu Y; Zheng M; Wang N; Wang R
    Med Sci Monit; 2019 Nov; 25():8492-8498. PubMed ID: 31710020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of epidermal growth factor receptor mutations and histologic subtypes with lung adenocarcinoma.
    Motono N; Funasaki A; Sekimura A; Usuda K; Uramoto H
    Med Oncol; 2018 Jan; 35(3):22. PubMed ID: 29387978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic impact according to the proportion of the lepidic subtype in stage IA acinar-predominant lung adenocarcinoma.
    Jeon HW; Kim YD; Sim SB; Moon MH
    Thorac Cancer; 2021 Jul; 12(14):2072-2077. PubMed ID: 34033216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential Prognostic Value of Vascular Invasion in Resected Lung Adenocarcinomas According to Epidermal Growth Factor Receptor Mutational Status.
    Lee KH; Chung JH; Cho S; Lee JS; Kim H
    Clin Lung Cancer; 2023 Nov; 24(7):e291-e299.e1. PubMed ID: 37479587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Validation of prognostic value of pathological staging in pathological stage Ⅰ lung adenocarcinoma].
    Zhang H; Sun FH; Chen ZC; Wang Q
    Zhonghua Wai Ke Za Zhi; 2022 Jun; 60(6):580-586. PubMed ID: 35658346
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of outcomes following lobectomy, segmentectomy, and wedge resection based on pathological subtyping in patients with pN0 invasive lung adenocarcinoma ≤1 cm.
    Song W; Hou Y; Zhang J; Zhou Q
    Cancer Med; 2022 Dec; 11(24):4784-4795. PubMed ID: 35570370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients.
    Russell PA; Barnett SA; Walkiewicz M; Wainer Z; Conron M; Wright GM; Gooi J; Knight S; Wynne R; Liew D; John T
    J Thorac Oncol; 2013 Apr; 8(4):461-8. PubMed ID: 23486266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognosis of epidermal growth factor receptor-mutated stage I lung adenocarcinoma with radiologically solid features.
    Hattori A; Matsunaga T; Fukui M; Takamochi K; Suzuki K
    Eur J Cardiothorac Surg; 2022 Mar; 61(4):769-777. PubMed ID: 34791156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.